A large analysis of 714 patients has looked at the risks associated with using teclistamab for relapsed or refractory multiple myeloma. The findings highlight a notable link between the treatment and the occurrence of infections.
According to the pooled data, about 56.5% of patients experienced some type of infection. More serious infections, classified as grade 3 or higher, were reported in 27.6% of the group. The analysis also noted differences in infection rates between those in clinical trials and those in real-world settings.
Specifically, the data showed that patients in clinical trials had a higher rate of any-grade infections (76.4%) compared to those in real-world evidence groups (45.4%). A similar trend was seen for more severe infections, which were more frequent in the clinical trial group.
While these findings provide important information about infection risks, it is important to note that this was a meta-analysis of existing data. Patients should discuss these specific risks and any concerns about infection with their oncology team.